12.2 Risk Factors & At-Risk Oncology Populations
Key Takeaways
- The Comprehensive Geriatric Assessment (CGA) evaluates functional status, comorbidities, cognition, nutrition, mobility, polypharmacy, and social support to predict chemotherapy toxicity and survival in older oncology adults (≥65 years).
- Validated geriatric chemotherapy toxicity calculators—such as the CARG (Cancer and Aging Research Group) score and CRASH (Chemotherapy Risk Assessment Scale for High-Age Patients) score—predict severe Grade 3–5 toxicities far more accurately than ECOG or Karnofsky performance status.
- Adolescent and Young Adult (AYA) oncology patients (ages 15–39) require mandatory, pre-treatment fertility preservation counseling regarding sperm cryopreservation, oocyte/embryo banking, and GnRH agonist suppression prior to initiating gonadotoxic therapy.
- LGBTQ+ oncology populations experience significant health disparities; culturally competent APRN care requires inclusive intake documentation, organ-based cancer screening matching anatomical structures, and mitigation of minority stress.
- Transitioning pediatric and AYA survivors to adult oncology care requires a structured, multi-step transition model incorporating survivorship passports, late-effects surveillance, and self-advocacy training.
Care for Special & Vulnerable Oncology Populations
Optimizing outcomes in oncology requires moving beyond standardized treatment protocols to address the unique physiological, developmental, and psychosocial characteristics of distinct vulnerable patient populations. Older adults (aging ≥65 years), Adolescents and Young Adults (AYAs, ages 15–39), sexual and gender minority (LGBTQ+) individuals, and pediatric cancer survivors transitioning to adult care face pronounced disparities, distinct physiological vulnerabilities, and unique survivorship challenges. For the Advanced Practice Registered Nurse (APRN), delivering high-quality oncology care mandates mastering comprehensive geriatric assessment tools, fertility preservation algorithms, culturally responsive communication, and structured transition frameworks.
1. Geriatric Oncology & Comprehensive Geriatric Assessment (CGA)
More than 60% of all cancer diagnoses and 70% of cancer-related mortality occur in adults aged 65 years and older. Chronological age alone is a poor predictor of physiological reserve, treatment tolerance, or chemotherapy toxicity.
The Comprehensive Geriatric Assessment (CGA)
The Comprehensive Geriatric Assessment (CGA) is a multidisciplinary diagnostic process used to evaluate an older patient's functional, physical, cognitive, and psychosocial capacity. Performing a CGA identifies unrecognized vulnerability, predicts severe treatment toxicities, guides regimen dose modifications, and informs survival estimates.
| Domain | Assessment Instrument | Clinical Implications & APRN Action |
|---|---|---|
| Functional Status (ADLs) | Katz Index of ADLs (Bathing, dressing, toileting, transferring, continence, feeding) | Dependence in ≥1 ADL indicates severe frailty; predicts high mortality and treatment intolerance. |
| Instrumental ADLs (IADLs) | Lawton-Brody IADL Scale (Using phone, shopping, food prep, housekeeping, laundry, transit, meds, finances) | IADL impairment predicts severe chemotherapy toxicity and loss of independent living during treatment. |
| Cognitive Function | Mini-Cog, Montreal Cognitive Assessment (MoCA), Blessed Orientation-Memory-Concentration | Unrecognized cognitive impairment impairs treatment adherence and informed consent. Avoid anticholinergic regimens. |
| Comorbidities | Cumulative Illness Rating Scale-Geriatrics (CIRS-G), Charlson Comorbidity Index (CCI) | High comorbidity burden increases non-cancer mortality risk; guides risk-benefit analysis of curative vs. attenuated regimens. |
| Polypharmacy & Medications | Beers Criteria for Potentially Inappropriate Medication Use in Older Adults | Evaluate for drug-drug interactions, renal clearing, and anticholinergic burden. Deprescribe high-risk medications. |
| Nutrition & Weight | Mini Nutritional Assessment (MNA), % involuntary weight loss | Involuntary weight loss >5% in 6 months indicates malnutrition/sarcopenia; increases chemotherapy toxicity risk. |
| Mobility & Fall Risk | Timed Up and Go (TUG) Test (Cutoff ≥12 seconds indicates high fall risk), Short Physical Performance Battery (SPPB) | Impaired TUG predicts falls and disability. Refer to physical therapy for mobility aids and balance conditioning. |
| Social Support & Mental Health | Geriatric Depression Scale (GDS-15), Social Support Rating | Social isolation increases vulnerability; arrange home health, meal delivery, and caregiver support. |
Predictive Chemotherapy Toxicity Models: CARG vs. CRASH
Traditional performance status measures like ECOG (0–4) or Karnofsky Performance Scale (KPS) fail to capture frailty in older adults. Two validated tools specifically predict Grade 3–5 chemotherapy toxicity in older patients:
- CARG Toxicity Score (Cancer and Aging Research Group): Incorporates age (≥72), cancer type, planned chemotherapy dose (full vs. reduced), polypharmacy, anemia, creatinine clearance, fall history, and IADL limitations. Stratifies patients into Low, Intermediate, or High risk for severe toxicity.
- CRASH Score (Chemotherapy Risk Assessment Scale for High-Age Patients): Evaluates hematologic and non-hematologic toxicity risk independently based on chemotherapy regimen intensity, baseline lymphocytes, cognition, IADLs, and diastolic blood pressure.
2. Adolescent & Young Adult (AYA) Oncology Care
Adolescent and Young Adult (AYA) oncology encompasses individuals aged 15 to 39 years at diagnosis. AYAs represent a distinct population wedged between pediatric and adult medical subspecialties, experiencing unique biological cancer drivers, delayed diagnoses, lower clinical trial enrollment rates, and profound developmental disruption.
Upfront Fertility Preservation & Counseling
ASCO guidelines mandate that all oncology clinicians address the risk of therapy-induced infertility with AYA patients as early as possible prior to initiating gonadotoxic surgery, radiation, or chemotherapy.
- Gonadotoxic Risk Factors: Alkylating agents (cyclophosphamide, ifosfamide, busulfan, melphalan), pelvic radiation, and bilateral gonadectomy cause severe germ cell depletion.
- Male Fertility Preservation Modalities:
- Sperm Cryopreservation (Sperm Banking): Gold standard; requires collecting 2–3 ejaculates prior to starting therapy.
- Testicular Tissue Cryopreservation: Experimental; reserved for prepubertal males.
- Female Fertility Preservation Modalities:
- Embryo Cryopreservation: Established standard; requires ovarian stimulation (10–14 days) and sperm donor/partner fertilization.
- Unfertilized Oocyte Cryopreservation (Egg Freezing): Standard of care for single females; requires ovarian stimulation.
- GnRH Agonist Suppression (e.g., Goserelin, Leuprolide): Administered during chemotherapy to induce temporary ovarian suppression; reduces risk of premature ovarian insufficiency (POI) in breast cancer patients, though less reliable than cryopreservation.
- Ovarian Tissue Cryopreservation: Option when treatment cannot be delayed for ovarian stimulation.
- Barriers & APRN Role: Financial cost, lack of insurance coverage, and urgency to start treatment represent major barriers. The APRN must initiate prompt referral to a reproductive endocrinology and infertility (REI) specialist immediately upon diagnosis.
3. LGBTQ+ Oncology Care & Health Disparities
Sexual and gender minority (LGBTQ+) individuals face documented health disparities, higher rates of specific cancers (e.g., anal cancer in MSM, breast/cervical cancer in sexual minority women due to lower historic screening rates), and significant minority stress in healthcare settings.
Culturally Competent APRN Practice Guidelines
- Inclusive Electronic Health Record (EHR) Documentation: Routinely capture Sexual Orientation and Gender Identity (SOGI) data, preferred name, and personal pronouns.
- Anatomical/Organ-Based Cancer Screening: Perform cancer screening based on present anatomical organs, regardless of gender identity or legal gender marker:
- Transgender men (AFAB) who retain a cervix require routine cervical Papanicolaou smears according to guidelines.
- Transgender women (AMAB) receiving feminizing hormone therapy retain a prostate gland and require prostate cancer screening evaluation when clinically indicated.
- Gender-Affirming Hormone Therapy (GAHT) Management: Hormone-sensitive cancers (e.g., ER+ breast cancer, prostate cancer) require multidisciplinary collaboration to navigate holding or adjusting GAHT while minimizing gender dysphoria.
4. Pediatric-to-Adult Oncology Transition Frameworks
With modern pediatric cancer cure rates exceeding 85%, over 500,000 pediatric cancer survivors currently live in the United States. Up to 75% of pediatric survivors develop at least one chronic late health condition (e.g., secondary malignancies, cardiomyopathy, endocrinopathies, infertility) by 30 years post-treatment.
Components of Successful Care Transition
- Survivorship Passport / Passport for Care: Comprehensive document outlining primary pediatric diagnosis, detailed treatment history (cumulative anthracycline doses, radiation field maps), and risk-stratified organ surveillance recommendations.
- Transition Readiness Assessment: Assessing young adults' health literacy, self-advocacy skills, insurance navigation capabilities, and understanding of their late-effect risks prior to transferring care from pediatric oncologists to adult providers.
An oncology nurse practitioner is evaluating an 78-year-old male with newly diagnosed Stage IV non-small cell lung cancer prior to selecting a systemic therapy regimen. The patient has an ECOG performance status of 1. Which evidence-based assessment strategy should the APRN employ to accurately predict the patient's risk of severe Grade 3 to 5 chemotherapy toxicity?
A 24-year-old female is diagnosed with Stage IIB Hodgkin lymphoma. The medical oncologist plans to initiate 6 cycles of ABVD chemotherapy (doxorubicin, bleomycin, vinblastine, dacarbazine). Prior to initiating chemotherapy, what is the mandatory first-line action by the APRN regarding reproductive health?
A 36-year-old transgender man (assigned female at birth) who has been taking testosterone gender-affirming hormone therapy for 10 years presents to the oncology clinic for routine preventive health maintenance. The patient has not undergone lower gender-affirming surgery. How should the APRN manage cancer screening for this patient?